FMS — Fresenius Medical Care AG
Is FMS overbought or oversold? Here is the current MarketMoodz read.
Fresenius Medical Care AG (FMS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $21.86. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$21.86
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryMedical Care Facilities
See all oversold Healthcare stocks →
AI analysis
Fresenius Medical Care AG (FMS) is a large, cash-generative provider of dialysis products and services with structural demand from aging and chronic kidney disease populations. The company’s global scale, recurring revenue base and initiatives in home dialysis and biopharma services support multi-year growth potential, while steady free cash flow and distributions provide downside support. Near term, results will be sensitive to reimbursement trends (particularly U.S. payors), execution on new-service rollouts, cost inflation and currency moves. Sector flows into defensive healthcare and the company’s steady earnings profile provide some stability in a cautious market environment. Scenario outcomes hinge on reimbursement/regulatory developments and the pace at which home and specialty services contribute to revenue and margins.
Key factors
- Large, recurring revenue base from dialysis services and related products providing stable cash flows and predictable utilization
- Global scale and diversified geographic footprint (Europe, North America, emerging markets) supports pricing leverage and supply-chain efficiency
- Demographic tailwinds: aging populations and rising chronic kidney disease prevalence support structural demand growth
- Ongoing strategic push into home dialysis, connected devices and biopharma services which can raise long-term growth and margin profile if executed
- Relatively strong free cash flow and history of shareholder distributions enhances downside support
- Exposure to currency fluctuations (EUR/USD) that can materially impact reported results and margins
- Market environment is cautious with flows into defensive healthcare, which can support relative performance near-term
Risks
- Reimbursement pressure and regulatory scrutiny (notably U.S. Medicare/Medicaid dynamics and payment policies) that could compress revenue or margins
- Execution risk on scaling home dialysis and new-service rollouts; slower adoption would delay growth and margin improvement
- Legal and compliance exposure typical for large providers (litigation, investigations, regulatory fines)
- Macro and cost pressures: higher wage, energy or supply costs could erode margins if not offset by pricing
- Competitive pressure from other dialysis providers, device makers and alternative therapies
- Foreign-exchange volatility and geopolitical developments that affect international operations and reported results
- Potential capital intensity for network upgrades and new clinic openings that could weigh near-term FCF if growth initiatives ramp
See today's live rating, score and targets
Members see the live hourly rating for FMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.